3	1
	₹ ⁄≾.

0.2							(Rs. in Lac
	;		Unaudited		Un-Ai	udited	Audited
	Particulars		Quarter ender	i .		ths Ended	Year ended
Sr. No.		3 months ended	3 months ended	Corresponding 3 months ended in the previous period	Year to date figures for the Current period ended	Year to date figures for the Previous period ended	Previous accounting yea
		31.12.14	30.09.14	31.12.13	31.12.14	31.12.13	31.03.1
1	Sales/Income from operation(Net of Excise duty)	6078.34		3806.34	14019.08	8454.49	
3	Other Operating Income	216.26		3.31	488.97	20.85	
4	Total Net Income from Operation Expenditure	6294.60	4349.90	3809.65	14508.05	8475.34	12267.7
	(a) Increase / decrease in stock in trade & work in progress	(346.45)	1050.87	391.21	552,26	(109.86)	(544.6
	(b) Consumption of raw materials	4941.79	1698.64	2027.58	9406.14	5602.31	
	(c) Employees Cost	292.31	275.09	289.18	820.58	800.25	1024.
	(d) Depreciation	100.27	93.63	102.34	300.80	299.62	
	(e) Other expenditure	906.45		722.87	2292.67	1815.01	
	(f) Total Profit(+)/Loss(-) from operations before Other	5894.37	3863.39	3533.18	13372.45	8407.33	11692.
5	income, Finance cost and Exceptional Items(3-4)	400.23	486.51	276.47	1135.60	68.01	
	Other income	0.00	2.69	3.79	4.88	5.77	
7.	Profit (+) / Loss (-) from ordinary activities before Finance Cost & Exceptional Items(5+6)	400.23	489.20	280.26	1140.48	73.78	583.
	Finance Cost	270.75	273.64	290.28	815.74	767.27	974
	Profit(+)/Loss(-) from ordinary activities after Finance cost & Exceptional Items(7-8)	129.48	215.56	(10.02)	324.74	(693.49)	(390.0
	Exceptional Items	0.00		0.00	0.00		
11	Profit(+)/Loss(-) before Tax (9-10)	129.48		(10.02)	324.74	(693.49)	
12	Tax Expenses(incl Deferred Tax)	45.00		0.00	60.00	0.00	
	Net Profit(+)/Loss(-) after Tax (11-12)	84.48	200,56	(10.02)	264.74	(693.49)	
	Extraordinary Items	0.00		0.00	0.00		
	Net Profit(+)/Loss(-) for the period(13-14) Paid up Equity Share Capital (face value Rs.10/-each)	84.48 1317.82		(10.02) 1317.82	264.74 1317.82	(693.49)	
	Reserves excluding Revaluation Reserves as per	1317.62	1317,62	1317.02	1317.82	1317.82	1317
17	balance sheet of previous accounting year. Earning per share (EPS)	0.00	0.00	0.00	0,00	0.00	1004
	(a) Basic and diluted EPS before extraordinary items for	-					
	the period, for the year to date and for the previous year						
	(not to be annualized)	0.64	1.52	(0.07)	2.01	(5.26)	(2.
	(b) Basic and diluted EPS after extraordinary items for the period, for the year to date and for the previous year						
	(not to be annualized)	·0.64	1,52	(0.07)	2:01	(5.26)	(2.
	Non Promoters Shareholding			(4.4.7)		(5:25)	1 · · · ·
	- Number of shares	7628115		7602453	7628115	7602453	76281
	- Percentage of shareholding	57.88	57.88	57.69	57.88	57.69	57
20	Promoters and Promoter group Shareholding						ļ
_	a) Pledged/ Encumbered Number of Shares	5491228	5491228	5467708	5491228	5467708	54912
-	Percentage of Shares (as a % of the total	3491228	3491220	3407700	5491220	3407700	54912
-	shareholding of promoter & promoter group	98.94	98.94	98.06	98.94	98.06	98
	Percentage of Shares (as a % of the total	52.0	22.01	25.00	22,04	33.00	1
	share capital of the company) b) Non-encumbered	41.67	41.67	41.49	41.67	41.49	41.
	Number of Shares	58905	58905	108087	58905	108087	589
	Percentage of Shares (as a % of the total		1	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	11100	,,,,,,,,,	1
	shareholding of promoter & promoter group)	1.06	1.06	1.94	1.06	1.94	1.0
	Percentage of Shares (as a % of the total						
	share capital of the company)	0.45 3 Months	0.45	0.82	0.45	0.82	0.
		ended	1				
21	Investors Complaints:	31.12.14	1				
	Pending at the Beginning of the Quarter	Nil	1				
	Received during the Quarter Disposed of during the Quarter	1	1				
	Description of during the squared		1				

Notes:

- 1 The above results have been reviewed by the Audit Committee and thereafter, were taken on record by the Board of Directors of the Company at their meeting held on 23rd January 2015.
- 2 As the Company's business activity falls within a single primary business segment viz. "Manufacturing of Bulk Drugs" the disclosure requirements of Accounting Standard (As -17) "Segment Reporting" is not applicable.
- 3 Previous year figure are regrouped wherever necessary.

Remaining unresolved at the end of the Quarter

Place: Mumbai Date: 23.01.2015

FR.N.:106405W FR.N.:106405W FR.N.:106405W FR.N.:106405W

Nil

On Dehalf of Board of Directors For Mangalam Drugs & Organics Ltd

Chairman (Shri Govardhan M.Dhoot) 18, Bagaria House, 1st Floor, 31/33, Dr. M.B. Velkar Lane, Mumbai - 400 002. Tel.: 22036132/9821162679 E-mail: rakesh_milwani@hotmail.com

To
The Secretary
Stock Exchange, Mumbai
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400 001.

To,
National Stock Exchange of India Limited
"Exchange Plaza",
Bandra - Kurla Complex,
Bandra (E),

Mumbai – 400 051.

LIMITED REVIEW REPORT

We have reviewed the accompanying statement of unaudited financial results of Mangalam Drugs & Organics Ltd. having its registered office at Rupam Building, 3rd Floor, 239 P.D'Mello Road, Near GPO, Mumbai –400001; for the quarter and nine months ended 31st Dec'2014 except for the disclosures regarding 'Public share holding' and 'Promoter and Promoter group share holding' which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, Engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express such an opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Mumbai

Date: 23rd January, 2015.

ER.N.:106405NV X AIAN STEERED LAGGIOUNTANTS

ER.N.:106405NV X AIAN DE MARKET SL. AIAN STEERED LAGGIOUNTANTS

ER.N.:106405NV X AIAN STEERED LAGGIOUNTANTS

ER

PROPRIETOR: MILWANI ASSOCIATES

Membership No.36099

Firm Registration No.:106405W